Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

Phase 2

Completed

• Conditions: Depression; Cancer; Palliative Care
• Interventions: Drug: Ketamine Hydrochloride

• Registration Number: NCT03410446
• Lead Sponsor: University Health Network, Toronto

Brief Summary

This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-12-28
• Study First Submitted QC: 2018-01-18
• Study First Posted: 2018-01-25
• Study Start: 2018-07-16
• Primary Completion: 2021-11-27
• Study Completion: 2021-11-27
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-04
• Last Update Posted: 2022-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Provide written, voluntary informed consent prior to study enrollment. Participants must be capable of consenting to treatment as substitute decision makers will not be allowed to consent to the study on their behalf
• Males and females ≥ 18 years of age
• Patient is receiving palliative care at Princess Margaret Cancer Centre (PM) including all in-patient units and outpatients
• Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Major Depressive Disorder (MDD), with a current Major Depressive Episode (MDE)
• Depression severity must be in the moderate to severe range, as determined by a Montgomery-Åsberg Depression Rating Scale (MADRS) score greater than or equal to 20
• Participants must have a confirmed diagnosis of cancer and an estimated life expectancy of less than twelve months, as determined by the palliative care physician

Exclusion Criteria

• Presence of delirium or suspected delirium
• Severe hypertension or severe cardiac decompensation
• Previous stroke history
• History of intolerability, hypersensitivity or allergy to ketamine
• Patients with bipolar disorder, psychotic disorders, substance use disorders or active suicidality based on a Mini-International Neuropsychiatric Interview (MINI) conducted by a delegated physician will also be excluded
• Current symptoms of psychosis or perceptual disturbances of any kind per investigator discretion
• Pregnancy or breastfeeding women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ketamine	Ketamine Hydrochloride	Three doses of ketamine will be given intranasal: * Dose 1 will be 50 mg on Day 1 * Dose 2 will be between 50-100 mg on Day 4 * Dose 3 will be between 50-150 mg on Day 7

Primary Outcome Measures

Name	Time	Method
Greater than 25% of participants achieving a clinical response	Day 8	Montgomery-Åsberg Depression Rating Scale (MADRS) score decreasing by \>50%

Trial Locations

Locations (1)

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada